Rituximab Seems Safe and Effective for Systemic Sclerosis Rituximab Seems Safe and Effective for Systemic Sclerosis
Rituximab seemed to be a safe and effective treatment for systemic sclerosis in a placebo-controlled validation trial in Japan.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 21, 2021 Category: Consumer Health News Tags: Rheumatology News Source Type: news

New Biomarkers May Predict Course of ILD in Systemic Sclerosis New Biomarkers May Predict Course of ILD in Systemic Sclerosis
Radiographic assessment of interstitial lung disease (ILD) progression and proteins from bronchoalveolar lavage may independently provide better insight into prognoses of patients with systemic sclerosis.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 16, 2021 Category: Consumer Health News Tags: Rheumatology News Source Type: news

Online mental health therapy significantly aids the isolated, immunosuppressed in pandemic
(Michigan Medicine - University of Michigan) People with the rare autoimmune disease scleroderma, who likely experience more serious isolation during a global pandemic, saw their anxiety and depression improve after receiving online mental health intervention through an international study. Researchers say the program could be extended to many vulnerable patient populations moving forward. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - June 16, 2021 Category: Infectious Diseases Source Type: news

The UCLA GIT 2.0 as a Decision Aid in Systemic Sclerosis The UCLA GIT 2.0 as a Decision Aid in Systemic Sclerosis
Learn more about the potential role the UCLA GIT 2.0 could have in the management of systemic sclerosis.Arthritis Research & Therapy (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 10, 2021 Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news

Tocilizumab Preserves Lung Function in Early Systemic Sclerosis
Stabilization of lung function independent of the extent of quantitative radiographic interstitial lung disease or fibrosis at baseline (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - April 23, 2021 Category: Respiratory Medicine Tags: Dermatology, Pharmacy, Pulmonology, Radiology, Rheumatology, Journal, Source Type: news

Tocilizumab Preserves Lung Function in Early Systemic Sclerosis
FRIDAY, April 23, 2021 -- Tocilizumab prevents progression of interstitial lung disease in patients with early systemic sclerosis (SSc), according to a study recently published in Arthritis& Rheumatology. David Roofeh, M.D., from the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 23, 2021 Category: Pharmaceuticals Source Type: news

For scleroderma, algorithm helps better screen for fatal complication
(Michigan Medicine - University of Michigan) A portion of people with the scleroderma develop pulmonary arterial hypertension, which can cause the heart to weaken and fail. Current screening methods may miss one in three patients with this sometimes fatal complication. But one computer algorithm, according to this study, will significantly improve the accuracy and help physicians treat it earlier. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 21, 2021 Category: International Medicine & Public Health Source Type: news

Screening for skin disease on your laptop
(University of Houston) A University of Houston biomedical engineer is reporting a new deep neural network architecture - to be used on a standard laptop - that provides early diagnosis of systemic sclerosis (SSc), a rare autoimmune disease marked by hardened or fibrous skin and internal organs. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 6, 2021 Category: International Medicine & Public Health Source Type: news

Combination therapy in systemic sclerosis-related pulmonary arterial hypertension: survival benefits at high cost
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - April 1, 2021 Category: Drugs & Pharmacology Source Type: news

Repurposing tocilizumab in scleroderma patients may prevent early lung disease
(Michigan Medicine - University of Michigan) A phase 3 clinical trial finds an anti-inflammatory drug used in rheumatoid arthritis can preserve lung function in patients with systemic sclerosis. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - March 31, 2021 Category: International Medicine & Public Health Source Type: news

Tocilizumab Scores FDA Approval for SSc-ILD Tocilizumab Scores FDA Approval for SSc-ILD
Tocilizumab is the first biologic to be approved by the agency for adults with systemic sclerosis –associated interstitial lung disease, a rare, potentially life-threatening condition.FDA Approvals (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - March 8, 2021 Category: Drugs & Pharmacology Tags: Rheumatology News Alert Source Type: news

Roche ’s Actemra/RoActemra becomes the first biologic therapy approved by the FDA for slowing the rate of decline in pulmonary function in adults with systemic sclerosis-associated interstitial lung disease, a rare, debilitating condition
Basel, 05 March 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) approved Actemra®/RoActemra® (tocilizumab) subcutaneous injection for slowing the rate of decline in pulmonary function in adult patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD), a debilitating condition with limited treatment options. Actemra/RoActemra is the first biologic therapy approved by the FDA for the treatment of the disease. Systemic sclerosis (SSc), also known as scleroderma, is an often devastating autoimmune disease that worsens over time and has no ...
Source: Roche Investor Update - March 5, 2021 Category: Pharmaceuticals Source Type: news

Roche ’s Actemra/RoActemra becomes the first biologic therapy approved by the FDA for slowing the rate of decline in pulmonary function in adults with systemic sclerosis-associated interstitial lung disease, a rare, debilitating condition
Basel, 05 March 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) approved Actemra®/RoActemra® (tocilizumab) subcutaneous injection for slowing the rate of decline in pulmonary function in adult patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD), a debilitating condition with limited treatment options. Actemra/RoActemra is the first biologic therapy approved by the FDA for the treatment of the disease. Systemic sclerosis (SSc), also known as scleroderma, is an often devastating autoimmune disease that worsens over time and has no ...
Source: Roche Media News - March 5, 2021 Category: Pharmaceuticals Source Type: news

Tocilizumab May Improve Lung Function in Early Systemic Sclerosis Tocilizumab May Improve Lung Function in Early Systemic Sclerosis
Treatment with tocilizumab could stabilize or improve lung function in people with early interstitial lung disease associated with systemic sclerosis.Medscape Medical News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - February 19, 2021 Category: Dermatology Tags: Rheumatology News Source Type: news

New research finds connection: Inflammation, metabolism and scleroderma scarring
(Michigan Medicine - University of Michigan) Study finds NAD+ break down leads to multi organ scarring, providing now a previously undiscovered pathogenic role of the enzyme CD38 in disease scarring. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 19, 2021 Category: International Medicine & Public Health Source Type: news

SARS-CoV-2 Pandemic Impacts on Systemic Sclerosis Patients SARS-CoV-2 Pandemic Impacts on Systemic Sclerosis Patients
What challenges have systemic sclerosis patients had to overcome due to the COVID-19 pandemic in terms of their disease management?Journal of Clinical Rheumatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 13, 2021 Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news

Protein linked to progressive lung scarring in scleroderma patients
(Michigan Medicine - University of Michigan) Osteopontin is discovered as the culprit behind systemic sclerosis patients' main cause of death: lung fibrosis. However, a repurposed immunosuppressive drug may combat the pro-inflammatory protein. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 17, 2020 Category: International Medicine & Public Health Source Type: news

Older Age Onset of Systemic Sclerosis Older Age Onset of Systemic Sclerosis
Systemic sclerosis may more rapidly progress among individuals who develop the disease later in life.Rheumatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 1, 2020 Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news

One step for fibrosis, one giant leap for scleroderma
(Medical University of South Carolina) At the Medical University of South Carolina, a team of researchers has demonstrated a " moonlighting " role for lysyl oxidase (LOX) in scleroderma. It was previously known that LOX crosslinked the connective tissue. However, this research showed that, independent of its crosslinking function, LOX plays multiple additional roles in promoting fibrosis in scleroderma, known as " moonlighting. " Furthermore, these researchers demonstrated that LOX could be a potential biomarker and target for antifibrotic therapy. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 16, 2020 Category: International Medicine & Public Health Source Type: news

Interstitial lung disease associated with systemic sclerosis large burden
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - November 1, 2020 Category: Drugs & Pharmacology Source Type: news

Abatacept as Treatment for Diffuse Cutaneous Systemic Sclerosis Abatacept as Treatment for Diffuse Cutaneous Systemic Sclerosis
' Exploratory outcome measures during the open-label extension, including the composite ACR CRISS score, indicate that abatacept might promote overall global improvement in these participants. 'Medscape Medical News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - October 29, 2020 Category: Dermatology Tags: Rheumatology News Source Type: news

Systemic Sclerosis Patients Share Their Needs in Treatment Trials Systemic Sclerosis Patients Share Their Needs in Treatment Trials
Patients with systemic sclerosis have variable disease progression but often experience debilitating fatigue, pain, and digestive issues; and they're extremely concerned about progressive organ damage.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 26, 2020 Category: Consumer Health News Tags: Rheumatology News Source Type: news

Stretches of repeating DNA predispose to systemic sclerosis
(University of Tsukuba) Researchers from the University of Tsukuba found that extended repeats of DNA in the gene FLI1 are associated with systemic sclerosis. By comparing the DNA of systemic sclerosis patients with healthy controls, they found that GA repeats over 22 are associated with the development of the disease as well as with a more severe outcome. These findings help us understand how FLI1 may contribute to the pathogenesis of systemic sclerosis. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - August 3, 2020 Category: Biology Source Type: news

Scleroderma: your questions about the autoimmune disease answered
Yale Medicine ’s Dr. Monique Hinchcliff, director of the Yale Scleroderma Program, offers valuable information about the difficult-to-diagnose disorder. (Source: Yale Science and Health News)
Source: Yale Science and Health News - July 15, 2020 Category: Universities & Medical Training Source Type: news

EC_approval_nintedanib_ILD_PF
European Commission approves third nintedanib indication in pulmonary fibrosis1The approval is for the treatment of adults with other chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype beyond idiopathic pulmonary fibrosis (IPF).1The decision is based on the results of the INBUILD ® trial, the first study to evaluate patients with a broad range of chronic fibrosing interstitial lung diseases (ILDs) and a progressive disease behavior.2Nintedanib is already approved in more than 80 countries for the treatment of idiopathic pulmonary fibrosis (IPF), and for systemic sclerosis-associated inters...
Source: Boehringer Ingelheim Corporate News - July 15, 2020 Category: Research Source Type: news

Pulmonary Function Tests Not a Good Substitute in ILD Screening Pulmonary Function Tests Not a Good Substitute in ILD Screening
Any screening algorithm should include high-resolution CT, which is good at prognosticating disease, say the authors of a retrospective study of 212 patients with systemic sclerosis.Medscape Medical News (Source: Medscape Rheumatology Headlines)
Source: Medscape Rheumatology Headlines - July 6, 2020 Category: Rheumatology Tags: Rheumatology News Source Type: news

In Scleroderma, GERD Questionnaires Are Essential Tools In Scleroderma, GERD Questionnaires Are Essential Tools
Every rheumatologist should be comfortable using a validated symptom scale for evaluating gastroesophageal reflux disease in patients with scleroderma, according to one expert.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 26, 2020 Category: Consumer Health News Tags: Rheumatology News Source Type: news

Be Vigilant for Scleroderma Renal Crisis Be Vigilant for Scleroderma Renal Crisis
A vexing feature of this emergency is that not uncommonly it actually precedes the diagnosis of scleroderma.Medscape Medical News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - June 19, 2020 Category: Dermatology Tags: Rheumatology News Source Type: news

What Triggers Scleroderma
? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - May 30, 2020 Category: General Medicine Source Type: news

CHMP_opinion_nintedanib_ILD_PF
Boehringer Ingelheim receives positive CHMP opinion for a third nintedanib indication in pulmonary fibrosis1The opinion is for the treatment of adults with other chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype beyond idiopathic pulmonary fibrosis (IPF).2The U.S. Food and Drug Administration (FDA) and Health Canada recently approved nintedanib as the first treatment for the same patient population.3,4Nintedanib is already approved in more than 80 countries for the treatment of idiopathic pulmonary fibrosis (IPF), and for systemic sclerosis-associated interstitial lung disease (SSc-ILD) in mo...
Source: Boehringer Ingelheim Corporate News - May 29, 2020 Category: Research Source Type: news

Impact of organ involvement on healthcare utilisation for systemic sclerosis in England
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - April 30, 2020 Category: Drugs & Pharmacology Source Type: news

European_Commission_approves_nintedanibSSc-ILD
European Commission approves nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease (SSc-ILD)Approval is based on the SENSCIS ® study which showed nintedanib slows the loss of pulmonary function in people living with systemic sclerosis-associated ILD (SSc-ILD)1Following the FDA ’s approval in September 2019, nintedanib in SSc-ILD has so far been approved in 15 countries including Canada, Japan and BrazilBeing the first and only approved treatment option available for people living with SSc-ILD, the approval constitutes a breakthrough in an area of high unmet need (Source: Boehring...
Source: Boehringer Ingelheim Corporate News - April 21, 2020 Category: Research Source Type: news

I ’ve Seen Wars and Epidemics Unfold. But Now That I Have an Immunocompromised Partner, the Coronavirus Makes Me Truly Scared
At midnight on Thursday March 26, all of South Africa went into lockdown. For the next 21 days, no one is to leave their homes unless they are going to the grocery store, the pharmacy or to seek medical help. No dog walking, no jogging, no food delivery services. Only essential workers are exempt, and that list is small. When President Cyril Ramaphosa made the announcement on March 23, a week after shutting the nation’s schools, there were only 402 confirmed COVID-19 cases. But it was essential, he said, to “flatten the curve” before widespread outbreaks overwhelmed the country’s fragile medical sys...
Source: TIME: Health - March 27, 2020 Category: Consumer Health News Authors: Aryn Baker Tags: Uncategorized COVID-19 feature Londontime Source Type: news

CHMP_opinion_Nintedanib_SSc-ILD
Boehringer Ingelheim receives positive CHMP opinion for nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease  Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion for nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease (SSc-ILD) in adults1Based upon positive SENSCIS ® trial results nintedanib was approved as the first and only therapy in the U.S. to slow the rate of decline in pulmonary function in patients with SSc-ILD2Nintedanib is already approved in more than 70 countries for the tre...
Source: Boehringer Ingelheim Corporate News - February 28, 2020 Category: Research Source Type: news

High-Res CT Has Key Role Detecting Lung Disease in Systemic Sclerosis High-Res CT Has Key Role Detecting Lung Disease in Systemic Sclerosis
The first evidence-based consensus statements for systemic sclerosis-associated interstitial lung disease (SSc-ILD) recommend use of high-resolution computed tomography (CT) for screening and diagnosis, and offer guidance on when to initiate or escalate emerging treatment options.Reuters Health Information (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - February 4, 2020 Category: Radiology Tags: Rheumatology News Source Type: news

Hyaluronic Acid and Platelet-Rich Plasma for Scleroderma Hyaluronic Acid and Platelet-Rich Plasma for Scleroderma
Scleroderma patients treated with filler injections of hyaluronic acid and platelet-rich plasma realized improvements in skin atrophy and quality of life.Arthritis Research & Therapy (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - January 28, 2020 Category: Pathology Tags: Rheumatology Journal Article Source Type: news

Garmin's Kao donates $20M to create institute within hospital
Garmin Ltd. co-founder and Executive Chairman Min Kao has donated $20 million to a nonprofit Los Angeles hospital. The gift from the Kao Family Foundation will create the Kao Autoimmunity Institute to advance research and treatment of rheumatologic diseases at Cedars-Sinai Medical Center, according to a Tuesday release. The donation also will establish a program within the institute that provides training and education for people with scleroderma, a disease that causes chronic hardening and tightening… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - December 12, 2019 Category: Biotechnology Authors: Lily Lieberman Source Type: news

Researchers create accurate model of organ scarring using stem cells in a lab
Every organ in the body is capable, to some extent, of repairing itself after an injury. As part of this process, scar tissue forms and then recedes to make room for normal tissue when healing is complete.However, when healing is disrupted — whether by chronic injury or disease — the cells that make up scar tissue can go rogue, continuously dividing and spreading until the scar eventually strangles the organ it was intended to help heal, which can lead to organ failure.That progressive, out-of-control scarring is called fibrosis, and it can occur in any organ in the body. Fibrosis plays a major role in many dis...
Source: UCLA Newsroom: Health Sciences - December 11, 2019 Category: Universities & Medical Training Source Type: news

Systemic Sclerosis Highlights From 2019 ACR Annual Meeting Systemic Sclerosis Highlights From 2019 ACR Annual Meeting
Dr Robert Spiera of the Hospital for Special Surgery in New York City reviews key studies related to systemic sclerosis, presented at the 2019 American College of Rheumatology annual meeting.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 6, 2019 Category: Consumer Health News Tags: Rheumatology ReCAP Source Type: news

FDA Approves First Treatment for ILD With Systemic Sclerosis, Scleroderma
Title: FDA Approves First Treatment for ILD With Systemic Sclerosis, SclerodermaCategory: Health NewsCreated: 9/10/2019 12:00:00 AMLast Editorial Review: 9/10/2019 12:00:00 AM (Source: MedicineNet Arthritis General)
Source: MedicineNet Arthritis General - September 10, 2019 Category: Rheumatology Source Type: news

FDA Approves First Treatment, Ofev (Nintedanib), for ILD With Systemic Sclerosis, Scleroderma
MONDAY, Sept. 9, 2019 -- The U.S. Food and Drug Administration granted the first approval for a drug to slow the decline of pulmonary function in interstitial lung disease associated with systemic sclerosis or scleroderma (SSc-ILD), the agency... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - September 9, 2019 Category: General Medicine Source Type: news

FDA OKs Nintedanib (Ofev) for Rare Lung Disease FDA OKs Nintedanib (Ofev) for Rare Lung Disease
Nintedanib capsules are approved for slowing the rate of decline in pulmonary function in adults with systemic sclerosis-associated interstitial lung disease.News Alerts (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - September 9, 2019 Category: Allergy & Immunology Tags: Pulmonary Medicine News Source Type: news

FDA-approves-nintedanib-in-SSc-ILD
FDA approves Ofev ® as the first and only therapy in the U.S. to slow the rate of decline in pulmonary function in patients with systemic sclerosis-associated ILDInterstitial lung disease (ILD) is the leading cause of death among people with systemic sclerosis (SSc) or scleroderma3  Approval is based on results from the Phase III SENSCIS ® study, the largest randomized controlled trial in SSc-ILD patientsRegulatory review of the additional indication in other countries is still ongoingOfev ® (nintedanib) is already approved in the U.S. and more than 70 countries for the treatment of idiopathic pulmonary fi...
Source: Boehringer Ingelheim Corporate News - September 9, 2019 Category: Research Source Type: news

FDA approves first treatment for patients with rare type of lung disease
The U.S. Food and Drug Administration has approved Ofev (nintedanib) capsules to slow the rate of decline in pulmonary function in adults with interstitial lung disease associated with systemic sclerosis or scleroderma, called SSc-ILD. It is the first FDA-approved treatment for this rare lung condition. (Source: World Pharma News)
Source: World Pharma News - September 9, 2019 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news

FDA Approves Ofev (nintedanib) for Interstitial Lung Disease Associated with Systemic Sclerosis or Scleroderma (SSc-ILD)
September 06, 2019 -- The U.S. Food and Drug Administration today approved Ofev (nintedanib) capsules to slow the rate of decline in pulmonary function in adults with interstitial lung disease associated with systemic sclerosis or scleroderma,... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - September 6, 2019 Category: Drugs & Pharmacology Source Type: news

FDA Panel Recommends Nintedanib for Rare Lung Disease FDA Panel Recommends Nintedanib for Rare Lung Disease
Small effect size for primary endpoint in systemic sclerosis-associated interstitial lung disease study, and lack of significant difference between groups for secondary outcomes, were sticking points.Medscape Medical News (Source: Medscape Rheumatology Headlines)
Source: Medscape Rheumatology Headlines - July 26, 2019 Category: Rheumatology Tags: Rheumatology News Source Type: news

Higher oestrogen levels linked to scleroderma severity
Older men with severe scleroderma have higher oestrogen levels than postmenopausal women with scleroderma, according to research published inArthritis Research& Therapy.Science Daily  (Source: Society for Endocrinology)
Source: Society for Endocrinology - June 10, 2019 Category: Endocrinology Source Type: news

Higher estrogen levels linked to more severe disease in scleroderma
(Medical University of South Carolina) Scleroderma is a connective tissue disease that hardens the skin and scars the organs. Older men with scleroderma had higher estrogen levels than healthy older men or postmenopausal women with scleroderma, report Medical University of South Carolina and University of Pittsburgh researchers in Arthritis Research& Therapy. Higher estradiol levels were associated with more severe disease and heart involvement in these men and, in those positive for the autoantibody Scl-70, a greater risk of death. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - June 5, 2019 Category: International Medicine & Public Health Source Type: news

Using New Autoantibodies in Rheumatic Disease: An Update Using New Autoantibodies in Rheumatic Disease: An Update
Dr Kevin Deane explains how recent advances are shining a light on the potential role that newer autoantibodies may play in the clinical care of RA, myositis, and scleroderma.Medscape Rheumatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 23, 2019 Category: Consumer Health News Tags: Rheumatology Viewpoint Source Type: news

nintedanib slows pulmonary function loss in people with ssc-ild
Phase III study showed nintedanib slows the loss of pulmonary function in people living with systemic sclerosis associated ILD1Results of pivotal Phase III SENSCIS ®trial published today in the New England Journal of Medicine (NEJM) and presented at the American Thoracic Society Conference in Dallas, USAInterstitial lung disease (ILD) is a key driver of mortality in people living with systemic sclerosis (SSc) – also known as scleroderma – and the absence of approved treatment options constitutes a high unmet need2,3FDA grants priority review to application for regulatory approval for nintedanib in patients ...
Source: Boehringer Ingelheim Corporate News - May 20, 2019 Category: Research Source Type: news